Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2022 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
December 20, 2021 08:00 ET | Source: FibroGen, Inc.

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...